Mirum Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Mirum Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 69.4% bzw. 25.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 70.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -21.4% betragen.

Wichtige Informationen

69.5%

Wachstumsrate der Gewinne

70.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	25.0%
Zukünftige Eigenkapitalrendite	-21.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:MIRM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	507	43	51	133	6
12/31/2025	405	-25	7	0	10
12/31/2024	313	-77	-28	-6	10
3/31/2024	224	-159	-42	-37	N/A
12/31/2023	186	-163	-91	-71	N/A
9/30/2023	145	-164	-104	-74	N/A
6/30/2023	116	-176	-112	-81	N/A
3/31/2023	96	-129	-115	-99	N/A
12/31/2022	77	-136	-120	-120	N/A
9/30/2022	52	-42	-138	-119	N/A
6/30/2022	39	-53	-146	-127	N/A
3/31/2022	32	-70	-166	-147	N/A
12/31/2021	19	-84	-152	-133	N/A
9/30/2021	16	-179	-136	-136	N/A
6/30/2021	11	-153	-119	-119	N/A
3/31/2021	N/A	-132	-96	-96	N/A
12/31/2020	N/A	-103	-89	-89	N/A
9/30/2020	N/A	-84	-67	-66	N/A
6/30/2020	N/A	-78	-65	-64	N/A
3/31/2020	N/A	-68	-56	-55	N/A
12/31/2019	N/A	-53	-40	-39	N/A
9/30/2019	N/A	-61	-38	-26	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MIRM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: MIRM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: MIRM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: MIRMDie Einnahmen des Unternehmens (25.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: MIRMDie Einnahmen des Unternehmens (25.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MIRM wird voraussichtlich in 3 Jahren unrentabel sein.

Mirum Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2026

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023

Price target decreased by 12% to US$48.30

Forecast breakeven date pushed back to 2025

Price target decreased by 7.2% to US$53.57

Recent updates

Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Forecast breakeven date pushed back to 2026

Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada’S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mirum Pharmaceuticals, Inc. announced delayed annual 10-K filing

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director recently sold US$157k worth of stock

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Price target decreased by 12% to US$48.30

Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting

Forecast breakeven date pushed back to 2025

Price target decreased by 7.2% to US$53.57

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Consensus estimates of losses per share improve by 22%

Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

Price target increased by 7.1% to US$59.20

Insider recently bought US$296k worth of stock

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Mirum Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Mirum Pharmaceuticals's LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

Forecast breakeven date moved forward to 2024

Mirum Pharmaceuticals, Inc. announced that it expects to receive $210 million in funding from Frazier Life Sciences Management, LP, Avidity Partners Management, L.P., BVF Partners L.P., Longitude Capital Management Co., LLC, Sofinnova Investment, Inc. and another investor

President recently sold US$141k worth of stock

Mirum Pharmaceuticals, Inc. Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

New major risk - Financial position

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Mirum Pharmaceuticals, Inc. Announces Data from It's LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. Announces Hepatology Communications Publishes Data from CAMEO Study Evaluating Safety, Tolerability, and Efficacy of LIVMARLI® (Maralixibat) Oral Solution in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals, Inc. Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

No longer forecast to breakeven

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Consensus revenue estimates increase by 16%

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer

Forecast to breakeven in 2025

Mirum Pharmaceuticals, Inc. Announces Resignation of Carol L. Brosgart, M.D. as A Director of the Company and as A Member of the Nominating and Corporate Governance Committee of the Board, Effective December 19, 2022

Mirum Pharmaceuticals, Inc. Appoints Lon Cardon to Board of Directors

Mirum Pharmaceuticals, Inc. Announces LIVMARLI (maralixibat) Approval by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

Mirum Pharmaceuticals Provides Development Program Updates

Forecast to breakeven in 2024

Mirum Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Mirum Pharmaceuticals, Inc. Reports Positive Topline Data from Its Phase 3 March Study

Price target increased to US$56.63

Mirum Pharmaceuticals, Inc. Announces Positive Topline Results from Its Pivotal Phase 3 March Study Evaluating Livmarli

Mirum Pharmaceuticals’ announces LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Price target decreased to US$51.43

No longer forecast to breakeven

Mirum Pharmaceuticals, Inc. Announces Resignation of Edward T. Mathers as A Member of the Compensation Committee of the Board, Effective September 1, 2022

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Mirum Pharmaceuticals announces $80M stock offering